$GWAV

Greenwave Technology Solutions, Inc. (GWAV): Entry into a Material Definitive Agreement

Greenwave Technology Solutions, Inc. (GWAV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement On August 24, 2026, Greenwave Technology Solutions, Inc. (the “Company”) entered into an Exchange Agreement with DWM Properties LLC (“DWM”), an entity controlled by Danny Meeks, the Chief Executive Officer of the Company (the

Original reporting
Published Aug 27, 2026, 8:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GWAV
Bearish
medium confidence
Mentioned
$GWAV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GWAVBearishMed
01

Why it matters

The transaction settles debt but introduces dilution, creating a mixed short‑term outlook.

02

Market read

Primary microcap news; may trigger immediate price reaction due to dilution.

03

What to watch

Potential strategic partnership with DWM Properties may bring non‑financial benefits.

Relevance 6/10Novelty 7/10Timing: after filing on Aug 27, 2026

Background

SEC Form 8‑K filing discloses a material definitive agreement and unregistered equity sale.

Company-level read

Ticker impact

$GWAVBearishMedium confidence
Context

Company issued 2,152,853 shares to settle a $5.39M promissory note and related party amounts.

Expected impact

Potential modest decline as new shares increase supply.

Evidence & confidence

Equity raise of ~2.1M shares represents significant dilution for a microcap, likely outweighing any immediate cash benefit.

Market effects

Limited impact; reflects ongoing financing activity in the technology services sector.

Minimal; confined to US microcap market.

Low; no broader market effect.

Counterpoint

The share issuance could improve balance sheet liquidity, supporting a short-term bounce.

Key entities

  • Greenwave Technology Solutions, Inc.

    Issuer of the shares and debtor.

  • DWM Properties LLC

    Counterparty receiving shares in settlement.

Related articles

$GWAVHighAI 9/10

Greenwave Announces Receipt of Additional Delinquency Notice from Nasdaq

Greenwave Technology Solutions said Nasdaq issued an additional delinquency notice on May 21, 2026 for its delayed Q1 2026 Form 10-Q filing, citing noncompliance with Nasdaq Listing Rule 5250(c)(1). The company previously received a delinquency notice for its late 2025 Form 10-K. Nasdaq gives until June 22, 2026 to submit a compliance plan; trading remains on Nasdaq under “GWAV.”

$CRWVHighAI 8/10

Why CoreWeave Is Tumbling Hard While the Market Is Soaring

CoreWeave (CRWV) shares fell 3.5% midday, underperforming the S&P 500's 0.9% rise, amid a $3.5B convertible note offering and 35M share ATM program, raising dilution concerns. The company has $72B in liabilities and a $626M Q2 net loss, despite strong demand and revenue growth. Analysts maintain an average $144 price target.

$QBTSHigh

QBTS Stock Rallies As U.S. Backs Quantum Expansion

D-Wave Quantum Inc. (QBTS) stock rose 7.87% on U.S. government backing and positive analyst coverage. The company secured up to $100M in CHIPS Act funding, and BMO Capital initiated coverage with a $35 price target. QBTS reported $24.6M annual revenue, negative margins, and $296.6M in cash. NTT DOCOMO's use of its quantum tech also drove interest.

$SNYLowAI 8/10

Sanofi announces new $925 million flu vaccine facility in Toronto

Sanofi announced a $925 million flu vaccine facility in Toronto, with partial funding from the federal government ($55 million) and the City of Toronto. The project is expected to create 300 jobs and enhance local vaccine supply. Premier Doug Ford emphasized Ontario's investment philosophy and the importance of domestic vaccine production.